Myovant Sciences Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYOV research report →
Companymyovant.com
Myovant Sciences Ltd. , a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
- CEO
- David C. Marek
- IPO
- 2016
- Employees
- 579
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $2.62B
- P/E
- -12.18
- P/S
- 11.36
- P/B
- -5.30
- EV/EBITDA
- -14.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 77.68%
- Op Margin
- -81.11%
- Net Margin
- -89.18%
- ROE
- 49.79%
- ROIC
- -68.92%
Growth & Income
- Revenue
- $230.97M · 289.39%
- Net Income
- $-205,981,000 · 19.27%
- EPS
- $-2.22 · 21.55%
- Op Income
- $-187,346,000
- FCF YoY
- -173.07%
Performance & Tape
- 52W High
- $27.06
- 52W Low
- $7.67
- 50D MA
- $26.92
- 200D MA
- $21.54
- Beta
- 2.15
- Avg Volume
- 1.09M
Get TickerSpark's AI analysis on MYOV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 23 | Valente Nancy | sell | 3,673 |
| Mar 10, 23 | Valente Nancy | sell | 36,892 |
| Mar 10, 23 | POTTER MYRTLE S | sell | 58,608 |
| Mar 10, 23 | POTTER MYRTLE S | sell | 21,603 |
| Mar 10, 23 | POTTER MYRTLE S | sell | 3,673 |
| Mar 10, 23 | POTTER MYRTLE S | sell | 21,096 |
| Mar 10, 23 | POTTER MYRTLE S | sell | 45,000 |
| Mar 10, 23 | Merendino Lauren | sell | 21,791 |
| Mar 10, 23 | Merendino Lauren | sell | 147,747 |
| Mar 10, 23 | Merendino Lauren | sell | 123,300 |
Our MYOV Coverage
We haven't published any research on MYOV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MYOV Report →